Lonza and Dalton Pharma Services enter into a co-operation agreement

November 15,2010 Basel, Switzerland

Lonza and Dalton Pharma Services enter into a co-operation agreement to better serve customers requesting early phase chemistry and kg-lab manufacturing services for Small Molecules.

Dalton's contract services are complementary to Lonza's value proposition in chemical custom manufacturing. With proximity to key customers in the North American pharmaceutical market they add desired geographic capability diversification to Lonza's existing facilities network that ranges from kg-lab to large scale manufacturing capabilities (ISO, cGMP) in Visp, Switzerland and Nansha, China. Dalton’s offering includes contract chemistry research, contract analytical services and chemical synthesis up to cGMP Kilogram-scale as well as small scale fill-finish activities at their site in Toronto, Canada.

The alliance will enable seamless transition of custom small molecule projects from Dalton's kg-lab scale through to Lonza's clinical and commercial manufacturing scale. Our joint customers will benefit from aligned interfaces and tech transfer efficiency gains, hence save valuable time and cost.

Dalton was identified as competent innovator and qualified as Lonza-trusted partner following a diligent selection and auditing process.


About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, the company had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.


About Dalton Pharma Services

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Further information can be found at www.dalton.com.


For further Information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540

Browse All News